Recombination sequence (RS) rearrangement frequency as a measure of central B cell tolerance
View Patent ↗The invention relates to methods and materials for diagnosing an autoimmune disease such as SLE, Type 1 diabetes, and the like. More particularly, the invention relates to methods and materials for assessing the frequency of recombination sequence (RS) rearrangement as a novel marker for an autoimmune disease. Such an assay can allow clinicians to diagnose an autoimmune disease based on the RS rearrangement frequency in an autoimmune patient as compared to an otherwise healthy control. In addition, the method includes identifying individuals who are at increased risk of developing autoimmunity. The method may also be helpful in directing the type of therapy and monitoring the effects of therapy in patients with autoimmune or non-autoimmune conditions.
1. A method for predicting a mammal's response to a type of B cell targeted therapy or immunomodulatory therapy, the method comprising measuring the frequency of recombination sequence (RS) rearrangements in B cells or B cell subsets from the mammal, and calibrating the measured frequency of RS rearrangement by at least one of B cell fraction and κ/λ ratio in the sample, wherein an altered level of RS rearrangement compared to the level of RS rearrangement in an otherwise identical healthy mammal provides a prediction of the response.
2. The method of claim 1 , wherein the method comprises measuring a reduced level of RS rearrangement compared to the level of RS rearrangement in an otherwise identical healthy mammal, thereby providing a prediction of the response.
3. The method of claim 1 , wherein the mammal has an autoimmune disease.
4. The method of claim 1 , further comprising obtaining DNA from a blood or tissue sample obtained from the mammal.
5. A method for predicting a mammal's response to a type of B cell targeted therapy or immunomodulatory therapy, the method comprising measuring the frequency of recombination sequence (RS) rearrangements in B cells or B cell subsets from the mammal, and calibrating the measured frequency of RS rearrangement by at least one of B cell fraction and κ/λ ratio in the sample, wherein an altered level of RS rearrangement compared to the level of RS rearrangement in an otherwise identical healthy mammal provides a prediction of the response; and administering a B cell targeted therapy or immunomodulatory therapy to the mammal.
6. The method of claim 5 , further comprising obtaining DNA from a blood or tissue sample obtained from the mammal.
7. The method of claim 5 , wherein the method comprises measuring a reduced level of RS rearrangement compared to the level of RS rearrangement in an otherwise identical healthy mammal, thereby providing a prediction of the response.